Integrated BioPharma (INBP) AI Stock Analysis

• Market Cap: $9.32M
• Dividend Yield: N/A
• Average Volume (3M): 15.15K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.05
• Revenue Growth: 4.72%
• EPS Growth: 55.24%
• Country: US
• Employees: 147
• Sector: Consumer Defensive
• Sector Strength: 42
• Industry: Packaged Foods
• EPS (TTM): -0.02
• Shares Outstanding: 31,059,610
• 10 Day Avg. Volume: 31,065
• 30 Day Avg. Volume: 15,153
• PEG Ratio: 0.02
• Price to Book (P/B): 0.53
• Price to Sales (P/S): 0.20
• P/FCF Ratio: 5.77
• Enterprise Value/Market Cap: 0.50
• Enterprise Value/Revenue: 0.09
• Enterprise Value/Gross Profit: 1.15
• Enterprise Value/Ebitda: 2.55
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 56 Neutral
• Price Target: $0.33 ▼(-3.24% Downside)
• Action: Reiterated Date: 02/12/26
• Date: Action: Reiterated 02/12/26

The score is held back primarily by weakening operating fundamentals (sharp TTM revenue decline, low gross margin, and a move back to net losses). Offsetting this are a low-risk balance sheet with minimal leverage and currently positive free cash flow. Technical indicators are mildly bearish/neutral and valuation is moderate, resulting in an overall mid-range score.

Positive Factors

Conservative balance sheet / low leverage

Very low leverage gives durable financial flexibility: the company can fund working-capital needs, weather sales volatility, and pursue opportunistic investments or contract wins without material refinancing risk, supporting stability over the next 2–6 months.

Positive operating and free cash flow

Consistent positive cash generation and rising free cash flow improve self-funding ability for capex, R&D, or working capital. This cash buffer mitigates earnings swings and supports operational continuity and contract-manufacturing obligations long term.

Integrated manufacturing and contract-manufacturing model

Owning manufacturing while serving third parties creates diversified revenue streams and captive capacity. This vertical capability supports margin stability, customer stickiness via contract relationships, and strategic flexibility to scale own brands or B2B volumes over time.

Negative Factors

Sharp revenue decline

A steep near-term revenue drop reduces scale economics and risks underutilized manufacturing capacity. If sustained, lower volumes will pressure fixed-cost absorption and make margins and profitability harder to restore over the medium term absent new contract wins or product growth.

Low and eroding gross margins

Sub-10–12% gross margins limit operating leverage and leave little room to absorb input cost inflation or pricing pressure. Persistently thin gross profit reduces the firm's ability to rebuild earnings from revenue growth and heightens sensitivity to commodity or labor cost shifts.

Profitability volatility / modest returns

Intermittent losses and modest ROE indicate inconsistent earnings power. Such volatility impairs long-term reinvestment and makes it harder to execute strategic initiatives reliably; investors and counterparties may demand stronger proof of sustained profit recovery.

Integrated BioPharma Business Overview & Revenue Model

Company Description

Integrated BioPharma, Inc., together with its subsidiaries, manufactures, distributes, markets, and sells vitamins, nutritional supplements, and herbal products primarily in the United States, Luxembourg, and Canada. It operates through Contract Manufacturing and Other Nutraceutical Businesses segments. The Contract Manufacturing segment manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers, and specialized healthcare providers. The Other Nutraceutical Businesses segment distributes healthful nutritional products for sale through mass market, grocery, drug, and vitamin retailers under the Peaceful Sleep and Wheatgrass brands, as well as other branded proprietary nutraceutical products. This segment also sells private label vitamin and nutritional supplement products through the Internet; provides warehousing and fulfilment services; and distributes fine natural botanicals, including multi minerals, as well as raw materials. The company was formerly known as Integrated Health Technologies, Inc. Integrated BioPharma, Inc. was incorporated in 1980 and is based in Hillside, New Jersey.

How the Company Makes Money

Integrated BioPharma generates revenue through multiple streams, primarily by selling its pharmaceutical and nutraceutical products directly to consumers and through partnerships with healthcare providers and distributors. The company's revenue model includes retail sales, online sales, and wholesale distribution. Additionally, INBP may engage in licensing agreements with other pharmaceutical companies for the development and commercialization of specific products, which can provide significant royalties and milestone payments. Strategic collaborations with research institutions and healthcare organizations also contribute to its earnings by enhancing product development and expanding market reach.

Integrated BioPharma Financial Statement Overview

Summary

Financials are mixed: the balance sheet is conservative with very low leverage (debt-to-equity ~0.03) and cash generation is positive (TTM operating cash flow $3.1M; free cash flow $2.8M, up ~17.6%), but operating performance has weakened materially with a steep TTM revenue decline (-23.6%), low gross margin (~10%), and a return to a small net loss.

Income Statement

Profitability has weakened meaningfully versus prior years. Revenue declined sharply in TTM (Trailing-Twelve-Months) (-23.6%) after modest growth in FY2025, and the company slipped to a small net loss in TTM (Trailing-Twelve-Months) after remaining profitable in FY2025. Gross profit margin is low (~10%) and down from the stronger levels seen in FY2021–FY2022, while operating profitability is positive but thin, leaving results more sensitive to cost pressure and volume declines.

Balance Sheet

The balance sheet looks conservative with very low leverage. Total debt is modest ($0.5M in TTM (Trailing-Twelve-Months)) relative to equity ($19.8M), with a low debt-to-equity ratio (~0.03), improving versus prior years. The main weakness is returns: return on equity is modest in the most recent periods and profitability volatility reduces the ability to consistently compound equity value.

Cash Flow

Cash generation is a relative bright spot. Operating cash flow and free cash flow are solid in TTM (Trailing-Twelve-Months) ($3.1M and $2.8M), with free cash flow growth up ~17.6%. However, cash flow performance has been uneven historically (notably weaker in FY2024), and recent cash conversion versus earnings is not especially strong, which suggests working-capital swings and/or non-cash items can materially affect reported profit versus cash.

Breakdown	TTM	Jun 2025	Jun 2024	Jun 2023	Jun 2022	Jun 2021
Income Statement
Total Revenue	52.09M	54.35M	50.32M	50.67M	56.25M	63.56M
Gross Profit	4.07M	5.56M	3.88M	4.06M	6.55M	9.48M
EBITDA	1.83M	3.38M	1.47M	1.27M	3.56M	6.61M
Net Income	-206.00K	808.00K	112.00K	-34.00K	3.84M	8.01M
Balance Sheet
Total Assets	23.55M	24.90M	26.21M	25.43M	25.25M	25.44M
Cash, Cash Equivalents and Short-Term Investments	5.31M	3.62M	1.68M	1.32M	331.00K	210.00K
Total Debt	649.00K	1.01M	1.80M	2.67M	2.06M	4.33M
Total Liabilities	3.78M	4.58M	6.97M	6.57M	6.67M	11.11M
Stockholders Equity	19.77M	20.32M	19.24M	18.86M	18.57M	14.33M
Cash Flow
Free Cash Flow	2.81M	1.87M	390.00K	1.12M	3.60M	2.75M
Operating Cash Flow	3.13M	2.06M	943.00K	1.23M	4.09M	3.05M
Investing Cash Flow	-317.00K	-205.00K	-553.00K	-111.00K	-465.00K	-199.00K
Financing Cash Flow	45.00K	78.00K	-29.00K	-136.00K	-3.50M	-3.04M

Integrated BioPharma Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.34
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For INBP, the sentiment is Negative. The current price of 0.34 is above the 20-day moving average (MA) of 0.31, above the 50-day MA of 0.33, and above the 200-day MA of 0.31, indicating a bearish trend. The MACD of -0.01 indicates Positive momentum. The RSI at 43.35 is Neutral, neither overbought nor oversold. The STOCH value of 72.78 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for INBP.

Integrated BioPharma Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	62 Neutral	$20.33B	14.63	-3.31%	3.23%	1.93%	-12.26%
INBP	56 Neutral	$9.32M	-42.86	3.36%	―	4.72%	55.24%
FTLF	55 Neutral	$141.62M	21.68	17.77%	―	12.44%	-20.33%
SOWG	48 Neutral	$5.62M	-0.22	-84.22%	―	-81.88%	-672.01%
NAII	46 Neutral	$16.74M	-1.35	-15.93%	―	18.19%	-35.22%
BON	46 Neutral	$13.33M	-5.82	1.32%	―	-15.44%	-94.04%
HCWC	46 Neutral	$5.52M	―	―	―	―	―

Integrated BioPharma Corporate Events

Integrated BioPharma Holds 2025 Annual Stockholder Meeting

On December 1, 2025, Integrated BioPharma, Inc. held its 2025 Annual Meeting of Stockholders, where 22,651,488 shares were represented, forming a quorum. The stockholders voted on four proposals, including the election of Eric Friedman as Class III director, a non-binding advisory vote on executive compensation frequency, approval of executive compensation, and ratification of CBIZ CPAs P.C. as independent auditors for the fiscal year ending June 30, 2026.

The most recent analyst rating on (INBP) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Integrated BioPharma stock, see the INBP Stock Forecast page.